BRPI0813436A2 - Particulados de ácido (4,6-bis (dimetilamino)-2-(4-(4-(trifluorometil) benzamido)-benzil)pirimindin-5-il} acético, composição farmacêutica, métodos para o tratamento, prevenção ou melhora de um ou mais sintomas de uma doença mediada por crth2, de uma doença relacionada com eosinófilo, de uma doença relacionada com basófilo, e de uma doença inflamatória, e, processo para a preparação dos particulados. - Google Patents

Particulados de ácido (4,6-bis (dimetilamino)-2-(4-(4-(trifluorometil) benzamido)-benzil)pirimindin-5-il} acético, composição farmacêutica, métodos para o tratamento, prevenção ou melhora de um ou mais sintomas de uma doença mediada por crth2, de uma doença relacionada com eosinófilo, de uma doença relacionada com basófilo, e de uma doença inflamatória, e, processo para a preparação dos particulados.

Info

Publication number: BRPI0813436A2
Authority: BR; Brazil
Prior art keywords: particulates; related disease; disease; basophyl; pyrimindin
Prior art date: 2007-06-21

Application number

BRPI0813436-7A2A

Other languages

English (en)

Inventor

Tai Wei Ly

Hui-Yin Li

Original Assignee

Actimis Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-06-21

Filing date

2008-06-18

Publication date

2014-12-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39708813&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0813436(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-06-18 Application filed by Actimis Pharmaceuticals Inc filed Critical Actimis Pharmaceuticals Inc

2014-12-23 Publication of BRPI0813436A2 publication Critical patent/BRPI0813436A2/pt

Links

201000010099 disease Diseases 0.000 title 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 3
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title 2
238000000034 method Methods 0.000 title 2
MAUMSNABMVEOGP-UHFFFAOYSA-N (methyl-$l^{2}-azanyl)methane Chemical class C[N]C MAUMSNABMVEOGP-UHFFFAOYSA-N 0.000 title 1
206010014950 Eosinophilia Diseases 0.000 title 1
230000002265 prevention Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Biomedical Technology (AREA)
Ophthalmology & Optometry (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)

BRPI0813436-7A2A 2007-06-21 2008-06-18 Particulados de ácido (4,6-bis (dimetilamino)-2-(4-(4-(trifluorometil) benzamido)-benzil)pirimindin-5-il} acético, composição farmacêutica, métodos para o tratamento, prevenção ou melhora de um ou mais sintomas de uma doença mediada por crth2, de uma doença relacionada com eosinófilo, de uma doença relacionada com basófilo, e de uma doença inflamatória, e, processo para a preparação dos particulados. BRPI0813436A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US93697207P	2007-06-21	2007-06-21
PCT/US2008/007589 WO2008156780A1 (en)	2007-06-21	2008-06-18	Particulates of a crth2 antagonist

Publications (1)

Publication Number	Publication Date
BRPI0813436A2 true BRPI0813436A2 (pt)	2014-12-23

Family

ID=39708813

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0813436-7A2A BRPI0813436A2 (pt)	2007-06-21	2008-06-18	Particulados de ácido (4,6-bis (dimetilamino)-2-(4-(4-(trifluorometil) benzamido)-benzil)pirimindin-5-il} acético, composição farmacêutica, métodos para o tratamento, prevenção ou melhora de um ou mais sintomas de uma doença mediada por crth2, de uma doença relacionada com eosinófilo, de uma doença relacionada com basófilo, e de uma doença inflamatória, e, processo para a preparação dos particulados.

Country Status (20)

Country	Link
US (1)	US8507005B2 (pt)
EP (1)	EP2170838A1 (pt)
JP (1)	JP2010530425A (pt)
KR (1)	KR20100023046A (pt)
CN (3)	CN101778830B (pt)
AR (1)	AR067119A1 (pt)
AU (1)	AU2008266853A1 (pt)
BR (1)	BRPI0813436A2 (pt)
CA (1)	CA2690172A1 (pt)
CL (1)	CL2008001818A1 (pt)
CO (1)	CO6290713A2 (pt)
EC (1)	ECSP109890A (pt)
IL (1)	IL202679A0 (pt)
MA (1)	MA31534B1 (pt)
NZ (1)	NZ581811A (pt)
RU (1)	RU2468012C2 (pt)
TN (1)	TN2009000518A1 (pt)
TW (1)	TW200911762A (pt)
UA (1)	UA99138C2 (pt)
WO (1)	WO2008156780A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1471057E (pt)	2003-04-25	2006-05-31	Actimis Pharmaceuticals Inc	Derivados de acido pirimidinilacetico uteis para o tratamento de doencas mediadas por crth2
EP2176240A1 (en) *	2007-06-21	2010-04-21	Actimis Pharmaceuticals, Inc.,	Amine salts of a crth2 antagonist
BRPI0907364A2 (pt)	2008-02-01	2015-07-14	Amira Pharmaceuticals Inc	Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
JP2011513242A (ja)	2008-02-25	2011-04-28	アミラファーマシューティカルズ，インク．	プロスタグランジンｄ２受容体アンタゴニスト
WO2010008864A2 (en)	2008-06-24	2010-01-21	Amira Pharmaceuticals, Inc.	Cycloalkane[b]indole angtagonists of prostaglandin d2 receptors
GB2463788B (en)	2008-09-29	2010-12-15	Amira Pharmaceuticals Inc	Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en)	2008-10-01	2010-04-08	Amira Pharmaceuticals, Inc.	Heteroaryl antagonists of prostaglandin d2 receptors
WO2010042652A2 (en)	2008-10-08	2010-04-15	Amira Pharmaceuticals, Inc.	Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
GB2465062B (en)	2008-11-06	2011-04-13	Amira Pharmaceuticals Inc	Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US20120142715A1 (en)	2009-07-06	2012-06-07	Boehringer Ingelheim International Gmbh	Polymorph of [4,6-bis(dimethylamino)-2-(4-benzyl)pyrimidin-5-yl]
EP2461809A4 (en)	2009-07-31	2013-06-19	Panmira Pharmaceuticals Llc	OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONSITES
US8815917B2 (en)	2009-08-05	2014-08-26	Panmira Pharmaceuticals, Llc	DP2 antagonist and uses thereof
EA201200765A1 (ru)	2009-11-24	2013-02-28	Бёрингер Ингельхайм Интернациональ Гмбх	Способ получения полиморфной модификации холиновой соли производного пиримидин-5-илуксусной кислоты
EP2504318A2 (en)	2009-11-24	2012-10-03	Boehringer Ingelheim International GmbH	Crystalline salt forms of a pyrimidin-5-yl acetic acid derivative
EP2457900A1 (en)	2010-11-25	2012-05-30	Almirall, S.A.	New pyrazole derivatives having CRTh2 antagonistic behaviour
EP3638208A1 (en) *	2017-06-12	2020-04-22	Novartis AG	Amorphous nanostructured pharmaceutical materials

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7078690B2 (en) *	2002-02-04	2006-07-18	Applied Materials, Israel, Ltd.	Monitoring of contact hole production
PT1471057E (pt) *	2003-04-25	2006-05-31	Actimis Pharmaceuticals Inc	Derivados de acido pirimidinilacetico uteis para o tratamento de doencas mediadas por crth2
CN100584844C (zh) *	2004-01-31	2010-01-27	艾克提麦斯医药品有限公司	咪唑[1,2-c]嘧啶基乙酸衍生物

2008
- 2008-06-18 US US12/665,706 patent/US8507005B2/en not_active Expired - Fee Related
- 2008-06-18 CA CA2690172A patent/CA2690172A1/en not_active Abandoned
- 2008-06-18 JP JP2010513234A patent/JP2010530425A/ja active Pending
- 2008-06-18 WO PCT/US2008/007589 patent/WO2008156780A1/en not_active Ceased
- 2008-06-18 EP EP08768582A patent/EP2170838A1/en not_active Withdrawn
- 2008-06-18 KR KR1020107001462A patent/KR20100023046A/ko not_active Ceased
- 2008-06-18 CN CN2008801032394A patent/CN101778830B/zh not_active Expired - Fee Related
- 2008-06-18 RU RU2010101804/04A patent/RU2468012C2/ru not_active IP Right Cessation
- 2008-06-18 UA UAA201000542A patent/UA99138C2/ru unknown
- 2008-06-18 AU AU2008266853A patent/AU2008266853A1/en not_active Abandoned
- 2008-06-18 BR BRPI0813436-7A2A patent/BRPI0813436A2/pt not_active IP Right Cessation
- 2008-06-18 CN CN2013100434078A patent/CN103172572A/zh active Pending
- 2008-06-18 CN CN2013100434631A patent/CN103172573A/zh active Pending
- 2008-06-18 NZ NZ581811A patent/NZ581811A/xx not_active IP Right Cessation
- 2008-06-19 CL CL2008001818A patent/CL2008001818A1/es unknown
- 2008-06-20 AR ARP080102676A patent/AR067119A1/es not_active Application Discontinuation
- 2008-06-20 TW TW097123253A patent/TW200911762A/zh unknown
2009
- 2009-12-10 IL IL202679A patent/IL202679A0/en unknown
- 2009-12-10 TN TNP2009000518A patent/TN2009000518A1/fr unknown
2010
- 2010-01-19 MA MA32538A patent/MA31534B1/fr unknown
- 2010-01-20 CO CO10005024A patent/CO6290713A2/es not_active Application Discontinuation
- 2010-01-21 EC EC2010009890A patent/ECSP109890A/es unknown

Also Published As

Publication number	Publication date
MA31534B1 (fr)	2010-07-01
RU2010101804A (ru)	2011-07-27
AU2008266853A1 (en)	2008-12-24
AR067119A1 (es)	2009-09-30
US8507005B2 (en)	2013-08-13
CL2008001818A1 (es)	2009-03-06
IL202679A0 (en)	2010-06-30
RU2468012C2 (ru)	2012-11-27
TN2009000518A1 (en)	2011-03-31
UA99138C2 (ru)	2012-07-25
TW200911762A (en)	2009-03-16
CN103172573A (zh)	2013-06-26
KR20100023046A (ko)	2010-03-03
CN101778830A (zh)	2010-07-14
WO2008156780A1 (en)	2008-12-24
ECSP109890A (es)	2010-03-31
EP2170838A1 (en)	2010-04-07
NZ581811A (en)	2012-11-30
US20110052701A1 (en)	2011-03-03
CA2690172A1 (en)	2008-12-24
JP2010530425A (ja)	2010-09-09
HK1144939A1 (en)	2011-03-18
CN101778830B (zh)	2013-03-20
CN103172572A (zh)	2013-06-26
CO6290713A2 (es)	2011-06-20

Similar Documents

Publication	Publication Date	Title
BRPI0813436A2 (pt)	2014-12-23	Particulados de ácido (4,6-bis (dimetilamino)-2-(4-(4-(trifluorometil) benzamido)-benzil)pirimindin-5-il} acético, composição farmacêutica, métodos para o tratamento, prevenção ou melhora de um ou mais sintomas de uma doença mediada por crth2, de uma doença relacionada com eosinófilo, de uma doença relacionada com basófilo, e de uma doença inflamatória, e, processo para a preparação dos particulados.
BRPI0821299A2 (pt)	2015-06-16	Composto, processo para preparar o mesmo, composição farmacêutica, processo para preparar a mesma, uso de um composto, e, método para tratar, ou reduzir o risco de, uma doença ou condição.
BRPI0717697A2 (pt)	2016-03-22	composto, composição farmaceutica, uso do composto, método para tratar um paciente sofrendo de uma condição patológica ou uma doença e combinação de produtos
BRPI0812597A2 (pt)	2015-02-18	Sal, composição farmacêutica, métodos para o tratamento, prevenção ou melhora de um ou mais sintomas de uma doença mediada por crth2, de uma doença relacionada com eosinófilo, de uma doença relacionada com basófilo, e de uma doença inflamatória, e, processo para a preparação do sal
BRPI1011593A2 (pt)	2016-03-22	"combinação farmacêutica, composição farmaceuticamente aceitavél, e, método para tratar um distúrbio metabólico, para tratar doença pulmonar obstrutiva crônica, e para tratar ou prevenir um ou mais distúrbios metabólicos."
BRPI0807749A2 (pt)	2014-06-17	Composto, composição farmacêutica, e, método para a prevenção, tratamento ou melhora de doenças ou condições dérmicas, ou distúrbios de ferida cutânea agudos ou crônicos.
NO20091183L (no)	2009-05-08	Derivater av 4-(N-azacykloalkyl)-anilider, fremgangsmåte for fremstilling av slike forbindelser, preparater omfattende slike forbindelser samt anvendelse av slike forbindelser for forhindring eller behandling av sykdom
BRPI1013396A2 (pt)	2016-03-29	composto, produto farmacêutico de combinação, uso de um composto, método para tratar uma doença ou condição, e, processo para a preparação de um composto.
PT1881823E (pt)	2015-03-02	Composições e métodos para o tratamento de transtornos oculares
LTC1562603I2 (lt)	2016-12-12	Nauji vaistai, skirti lėtinių obstrukcinių plaučių ligų gydymui
BRPI0818004A2 (pt)	2015-04-14	Composição farmacêutica sólida administrável por via oral e o processo da mesma.
BRPI0612109A2 (pt)	2016-09-06	composto, métodos de tratamento ou prevenção de uma doença, formulação farmacêutica, e, processo para preparar um composto
BRPI0819799A2 (pt)	2015-05-26	Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença
BRPI0820622A2 (pt)	2015-06-16	Compostos derivados de aminotiazol, processo para a sua preparação, composição farmacêutica que os compreende, uso dos mesmos e métodos para o tratamento e/ou profilaxia de diabetes e outras enfermidades
BRPI0807807A2 (pt)	2014-06-17	" composição farmacêutica de liberação modificada e um processo para fabricar a mesma ".
BRPI0814957A2 (pt)	2015-02-03	Composto, pró-droga, agente farmacêutico, método para a profilaxia ou tratamento de uma doença, distúrbio ou condição, e, uso do composto.
BRPI0917138A2 (pt)	2015-11-17	composto, métodos para tratar doenças alérgicas e outras condições inflamatórias, rinite alérgica, e para tratar ou prevenir doença, composição farmacêutica, uso de um composto, e, combinação.
BRPI0909985A2 (pt)	2015-08-25	Composição farmacêutica e método para o tratamento ou profilaxia de uma infecção viral ou doença associada à mesma
BRPI0814825A2 (pt)	2015-02-03	Composto, processo para a preparação do composto, composição farmacêutica que o compreende, seu uso e métodos para o tratamento ou profilaxia de diabetes, obesidade, distúrbios de alimentação ou dislipimedia e diabetes do tipo ii
BRPI0815696A2 (pt)	2016-06-21	composto derivados de benzimidazol, processo para a sua manufatura, composições farmacêuticas que os compreendem, metódo para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por agonistas de fxr e uso destes compostos.
BRPI0816881A2 (pt)	2015-03-17	Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
BRPI0917705A2 (pt)	2016-02-16	composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto
BRPI0717753A2 (pt)	2013-10-22	Método de tratamento ou redução do risco de uma doença causada por protozoários, e, composição.
EP2497482A4 (en)	2013-05-01	COMPOSITION FOR PROPHYLAXIS AND TREATMENT OF INFLUENZA AVIRUSED INDUCED DISEASES
BRPI0815591A2 (pt)	2015-03-03	Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio.

Legal Events

Date	Code	Title	Description
2015-12-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 6A E 7A ANUIDADES.
2016-03-29	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.